Getwell Hospital & Research Institute | Research Site

Research site

(Unclaimed)

Location

20/1, Dr, Khare Marg, Dhantoli, Nagpur, Maharashtra, India

Site insights

Top conditions

Top treatments

Durvalumab

Paclitaxel

Pembrolizumab

Capivasertib

Dapagliflozin

Saxagliptin

AZD9833

Nintedanib

Brazikumab

Camizestrant

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 61 total trials

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor)...

Active, not recruiting

ER-Positive HER2-Negative Breast Cancer

Drug: Palbociclib

Drug: Anastrozole

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared...

Enrolling

Metastatic Non-small Cell Lung Cancer

Drug: Pembrolizumab

Drug: Pemetrexed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalum...

Enrolling

Breast Cancer

Drug: Epirubicin

Drug: Olaparib

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling

Breast Cancer

Drug: Paclitaxel

Drug: Dato-DXd

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON)

This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety...

Enrolling

Hypereosinophilic Syndrome

Biological: Placebo

Biological: Benralizumab

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - e...

Enrolling

Breast Cancer, Early Breast Cancer

Drug: Exemestane

Drug: Anastrozole

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting

Breast Cancer

Drug: Paclitaxel

Drug: Eribulin mesylate

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (FORTUNA)

A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alc...

Active, not recruiting

Nonalcoholic Steatohepatitis

Other: Placebo

Drug: AZD2693

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER...

Enrolling

Breast Cancer, Early Breast Cancer

Drug: Exemestane

Drug: Letrozole

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormon...

Enrolling

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Drug: Palbociclib

Drug: Capivasertib

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) ve...

Active, not recruiting

Hormone-Sensitive Prostate Cancer

Drug: Capivasertib

Other: Placebo

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CAPItello-290)

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Tri...

Active, not recruiting

Triple Negative Breast Neoplasms

Drug: Capivasertib

Drug: Placebo

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by mainte...

Active, not recruiting

Endometrial Neoplasms

Drug: Carboplatin

Biological: durvalumab

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (OBERON)

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult...

Enrolling

Chronic Obstructive Pulmonary Disease (COPD)

Drug: Placebo

Drug: Tozorakimab

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (MIRANDA)

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with...

Enrolling

Chronic Obstructive Pulmonary Disease (COPD)

Drug: Placebo

Drug: Tozorakimab

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (EMERALD-3)

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients wit...

Enrolling

Hepatocellular Carcinoma

Procedure: Transarterial Chemoembolization (TACE)

Drug: Lenvatinib

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo co...

Enrolling

Chronic Obstructive Pulmonary Disease (COPD)

Combination Product: Tozorakimab 1

Combination Product: Placebo

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with...

Enrolling

Non-Small Cell Lung Cancer

Drug: Datopotamab Deruxtecan

Drug: Rilvegostomig

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA...

Enrolling

Metastatic Castration-Sensitive Prostate Cancer

Drug: Abiraterone Acetate

Drug: Placebo

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tre...

Active, not recruiting

Metastatic Urothelial Cancer

Unresectable Locally Advanced Urothelial Cancer

Drug: Cisplatin + Gemcitabine

Drug: Carboplatin + Gemcitabine